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Abstract
Background: The prognostic value of CA19-9 in patients with pancreatic cancer (PC) treated with
neoadjuvant therapy has not been well described.
Methods: Pre-treatment CA19-9 levels (with concomitant normal bilirubin level) in patients with local-
ized PC were categorized as normal (≤35), low (36–200), moderate (201–1000), or high (>1000). Post-
treatment CA19-9 was measured after neoadjuvant therapy, prior to surgery.
Results: Pre-treatment CA19-9 levels were evaluable in 235 patients, levels were normal in 60 (25%)
patients, low in 78 (33%) patients, moderate in 69 (29%) and high in 28 (12%). After neoadjuvant ther-
apy, post-treatment CA19-9 normalized (≤ 35) in 40 (51%) of the patients in the low group, 14 (21%) of
the moderate and 5 (19%) of the high group (P < 0.001). Of the 235 patients, 168 (71%) completed all
intended therapy including a pancreatectomy; 44 (73%), 62 (79%), 46 (67%) and 16 (57%) of the nor-
mal, low, moderate and high groups (P = 0.10). Among these 168 patients, the median overall survival
was 38.4, 43.6, 44.7, 27.2 and 26.4 months for normal, low, moderate and high CA19-9 groups (log
rank P = 0.72). Among resected patients, an elevated pre-treatment CA19-9 was of little prognostic
value; instead, it was the CA19-9 response to neoadjuvant therapy that was prognostic [hazard ratio
(HR): 1.80, P = 0.02].
Conclusions: Among patients who completed neoadjuvant therapy and surgery, pre-treatment CA19-9
obtained at the time of diagnosis was not predictive of overall survival, but normalization of post-
treatment CA19-9 in response to neoadjuvant therapy was highly prognostic.
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Introduction
In contrast to many other solid organ tumours, treatment
sequencing for patients with localized pancreatic cancer (PC)
remains highly controversial. A surgery-first strategy for
patients who ostensibly appear to have localized disease with
no radiographical evidence of metastases has yielded a 5-year
survival of only 15%, a statistic that has changed little in
over 30 years. 1,2 Systemic recurrence after a margin negative
(R0) resection occurs in the majority of patients, and this
observation supports the hypothesis that PC is a systemic dis-
ease, even in the absence of radiographical evidence of distant
metastases.3–5 Significant advances in surgical technique and
peri-operative management have dramatically reduced the 30-
day mortality after PC resection to <2%. However, the mor-
bidity of the surgical procedure coupled with the poor overall
oncological outcomes have undoubtedly contributed to the
nihilistic perceptions of the medical community, which may
have resulted in the underuse of PC surgery. 1,6 To reverse
the negative perception of the general medical community
regarding the utility of PC surgery, meaningful progress is
needed in both available treatments and the sequencing of
such treatments.
This study was presented at the Annual Meeting of the AHPBA, 11-15
March 2015, Miami, Florida.
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Radiographical staging can only detect measurable disease,
but blood-based biomarkers have the advantage of being
disease specific, quantitative and facilitate cost-effective moni-
toring of treatment response. For PC, serum levels of a carbo-
hydrate antigen (CA)19-9 has been extensively studied as a
prognostic biomarker. High pre-treatment CA19-9 levels have
been associated with poor prognosis in patients with resected
PC, as well as in patients with advanced-stage disease who
received chemotherapy.7–11 The outcomes of patients with a
very high pre-operative CA19-9 (> 1000) who were treated
with a surgery-first approach were particularly poor, prompt-
ing some clinicians to endorse a neoadjuvant strategy for this
population.12 The rationale for using neoadjuvant therapy is
obvious when systemic disease is suspected but not radio-
graphically confirmed, as it allows for the immediate delivery
of systemic therapy for the treatment of occult micrometasta-
ses. Patients who have an aggressive tumour biology and exhi-
bit disease progression while on therapy can be identified prior
to surgery and be spared an operation with limited oncological
benefit. In addition, serial measurements of CA19-9 levels prior
to therapy (pre-treatment) and after neoadjuvant therapy
(post-treatment) may be correlated with the treatment
response and survival and, thus, have an important clinical
prognostic value. A decrease in CA19-9 in response to neoad-
juvant therapy has previously been reported to correlate with
overall survival in two series of patients with localized PC.13,14
The purpose of this study was to evaluate the association of
pre-treatment and post-treatment CA19-9 levels on the com-
pletion of neoadjuvant therapy, including surgery, and overall
survival in patients with localized PC.
Patients and Methods
Study subjects
Using a prospectively maintained PC database at the Medical
College of Wisconsin (MCW), we reviewed consecutive
patients with resectable and borderline (BLR) PC who under-
went neoadjuvant therapy (with surgical intent) for biopsy-
proven adenocarcinoma of the pancreas from 2009 to 2014.
Patients with other histologies and patients with PC who did
not receive neoadjuvant therapy were excluded. Serum CA19-9
was measured at the author’s institution and evaluated at two
time points: prior to any neoadjuvant treatment (pre-treat-
ment) and after neoadjuvant treatment was completed and
prior to surgery (post-treatment). Pre-treatment and post-
treatment CA19-9 values were considered evaluable if the value
was identified when a concurrent serum total bilirubin value
was less than 2 mg/dl. Patients without an evaluable pre-treat-
ment CA19-9 were excluded. A CA19-9 cutpoint of 35 U/ml
was used to dichotomize patients with normal (≤ 35) and ele-
vated (> 35) values based on this institutional laboratory stan-
dard. Patients with an elevated CA19-9 were then further
stratified into low (36–200), moderate (201–1000) and high
(> 1000) groups.
The clinical stage at the time of diagnosis was determined
using objective radiographical criteria based on computed
tomography (CT) imaging to classify resectable or BLR dis-
ease.15 In addition, patients were also considered borderline
resectable if: (i) there were radiographical findings indeterminate
for metastatic disease, (ii) CA19-9 levels were > 2000 U/ml, or
(iii) if the patient’s baseline performance status was poor. The
age-adjusted Charlson’s comorbidity index (CCI) is a weighted
index that takes into account the number and seriousness of
the comorbid disease.16 The CCI was calculated by examining
the electronic medical record for explicit documentation of the
CCI comorbidity condition at the time of diagnosis/initial eval-
uation at our institution. This study was approved by the
MCW Institutional Review Board.
Treatment
All patients received neoadjuvant therapy consisting of chemo-
radiation and/or chemotherapy, either on or off protocol. The
majority of resectable patients received gemcitabine-based
chemoradiation, and the majority of BLR patients received
chemotherapy followed by chemoradiation. After the comple-
tion of neoadjuvant therapy, all patients underwent restaging
with a physical examination, laboratory studies and CT imag-
ing. Post-treatment CA19-9 levels were obtained 2–4 weeks
after the completion of neoadjuvant therapy. To be considered
for a pancreatectomy, patients were required to have: (i) the
absence of metastatic disease; (ii) ≤ 180° tumour abutment of
the superior mesenteric artery (SMA) or celiac artery, or short
segment encasement of the hepatic artery; (iii) suitable SMV
and PV to allow for venous reconstruction if necessary; and
(iv) an acceptable operative risk based on performance status,
physical examination and assessment of medical co-morbidi-
ties. Completion of all intended therapy was defined as the
completion of neoadjuvant therapy and surgical resection of
the PC. Our preferred surgical techniques for PD, distal pan-
createctomy and total pancreatectomy have been previously
described; a diagnostic laparoscopy was routinely performed
before a laparotomy.17 The pancreatectomy specimen was eval-
uated as per the current AJCC pathology recommendations
and the SMA margin of resection was considered positive (R1)
if ink was present at the margin; the pancreatic transection
margin and the hepatic duct margin were considered positive
if a tumour was present on the final assessment of the mar-
gin.18 Post-operative complications were recorded from the
database, verified in the electronic medical record and defined
by the Clavien criteria.19 Any Clavien grade 3+ complication
was considered a major complication. The length of hospital
stay was calculated by including the day of operation and
excluding the day of discharge. Readmission was defined as
admission to any hospital within 30 days of surgery. The deci-
sion to recommend post-operative, adjuvant therapy was based
on the opinion of the physician team and factors considered in
this decision included: the length and duration of neoadjuvant
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therapy, the findings on permanent pathology of the resected
specimen and the recovery of the patient. Adjuvant therapy
was not recommended for all patients.
Surveillance
All patients underwent follow-up at 3- to 4-month intervals
with a physical examination, laboratory studies and repeat CT
imaging. In the event of recurrent PC, we recorded the date
and location of recurrence and treatment. Recurrent disease
was assessed radiographically; tissue confirmation of disease
recurrence was rarely obtained. Disease-free survival was calcu-
lated from the date of diagnosis to the date of disease recur-
rence. Overall survival was calculated from the date of
diagnosis to the date of death or last follow-up.
Statistical analysis
Categorical variables were compared using Fischer’s Exact test.
All continuous variables were analysed using the Mann–Whit-
ney U-test. Survival and follow-up was calculated from the
time of initial diagnosis to the date of death or last follow-up.
Deaths from any cause were included in the survival analysis.
Overall survival was estimated using the Kaplan–Meier
method. We tested proportional hazard assumptions for all
variables associated with survival. All statistical analyses were
performed using Stata 13.1 (StataCorp, College Station, TX,
USA).
Results
Patient characteristics and pre-treatment CA19-9
From 2009 to 2014, 252 patients were identified with resect-
able or BLR PC, who were treated with neoadjuvant therapy.
Pre-treatment CA19-9 was not evaluable in 17 patients, and
they were excluded. Of the remaining 235 evaluable patients,
99 (42%) had resectable, and 136 (58%) had BLR PC. The
patient characteristics are summarized in Table 1. Of the 235
patients, CA19-9 levels were normal in 60 (25%) and elevated
in 175 (75%). Of the 60 patients with normal CA19-9, 2
(3%) had undetectable CA19-9 levels. The 175 patients
included 78 (33%) in the low group, 69 (29%) in the moder-
ate and 28 (12%) in the high subgroup. The median pre-
treatment CA19-9 for all 235 patients was 119 [interquartile
range (IQR): 487]; 14 (23), 79 (69), 488 (293) and 2297
(2350) for the normal, low, moderate and high groups,
respectively (P < 0.001). No differences were observed in age,
body mass index or Charlson’s Comorbidity Indices between
the subgroups.
Table 1 Demographics and neoadjuvant treatment outcomes
CA 19-9 category
Characteristic Total
n = 235
Normal
n = 60
Low
n = 78
Moderate
n = 69
High
n = 28
P-value
Age, years median (IQR) 65 (13) 66 (14) 65 (13) 65 (12) 62 (14) 0.83
Gender (Female), n (%) 115 (49) 36 (60) 37 (47) 32 (47) 10 (36) 0.16
BMI, median (IQR) 25 (7) 27 (8) 25 (6) 26 (8) 26 (6) 0.34
Charlson’s Comorbidity Index, median (IQR) 5 (2) 5 (2) 5 (2) 5 (2) 4 (3) 0.99
Pre-treatment CA19-9, U/ml median (IQR) 119 (487) 14 (23) 79 (69) 488 (293) 2297 (2350) <0.001
Post-treatment CA19-9, U/ml median (IQR) 36 (102) 9 (18) 34 (44) 107 (217) 194 (423) <0.001
Elevated Post-treatment CA19-9, n (%) 118 (51) 4 (7) 38 (49) 54 (79) 22 (81) <0.001
Clinical Stage, n (%) <0.001
Resectable 99 (42) 28 (47) 43 (55) 25 (36) 3 (11)
Borderline resectable 136 (58) 32 (53) 35 (45) 44 (64) 25 (89)
Neoadjuvant therapy, n (%)
Chemotherapy 42 (18) 12 (20) 11 (14) 12 (17) 7 (25) 0.06
Chemoradiation 86 (37) 21 (35) 40 (51) 20 (29) 5 (18) 0.001
Both 107 (45) 27 (45) 27 (35) 37 (54) 16 (57) 0.07
Completed Neoadjuvant and Surgery, n (%) 168 (71) 44 (73) 62 (79) 46 (67) 16 (57) 0.10
Did not undergo pancreatectomy, n (%) 0.77
Metastases 50 (21) 10 (17) 12 (15) 18 (26) 10 (36) 0.26
Local disease progression 4 (2) 2 (3) 1 (1) – 1 (4)
Medical comorbidities 12 (5) 3 (5) 3 (4) 5 (7) 1 (4)
Other 1 (0.4) 1 (2) – – –
IQR, interquartile range; BMI, body mass index; CA, carbohydrate antigen.
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Neoadjuvant therapy
Details of the neoadjuvant therapy administered are also sum-
marized in Table 1. Of the 235 patients, neoadjuvant therapy
consisted of chemotherapy alone, chemoradiation alone, or
both in 42 (18%), 86 (37%) and 107 (45%) patients, respec-
tively. No significant differences in neoadjuvant treatment were
observed between the normal, low and moderate pretreatment
CA19-9 subgroups. However, in the high group, only 5 (18%)
of the 28 patients received chemoradiation alone compared
with the low group, where 40 (51%) of the 78 patients received
chemoradiation alone (P = 0.009). Of the 99 patients with
resectable PC, 67 (68%) received chemoradiation alone, 29
(29%) received chemotherapy alone and 3 (3%) received both.
Of the 136 BLR patients, 104 (76%) received induction chemo-
therapy followed by chemoradiation, 19 (14%) received
chemoradiation alone and 13 (10%) received chemotherapy
alone.
Of all 235 patients, 168 (71%) completed all intended ther-
apy to include successful surgery; 44 (73%), 62 (79%), 46
(67%) and 16 (57%) of the normal, low, moderate and high
groups, respectively (P = 0.10). The most common reason why
surgery was not completed was the development of metastatic
disease progression discovered after neoadjuvant therapy that
occurred in 50 (21%) of the 235 patients; 10 (17%), 12 (15%),
18 (26%) and 10 (36%) of the normal, low, moderate and high
groups, respectively (P = 0.08). Local disease progression,
which precluded resection, occurred in 4 (2%) of the 235
patients, all of whom had BLR disease. An additional 12 (5%)
of the 235 patients had medical comorbidities that precluded a
resection. One individual of advanced age (88 years old)
elected not to pursue surgery after the completion of neoadju-
vant therapy.
Post-treatment (pre-operative) CA19-9
Of the 235 patients, 231(98%) had an evaluable post-treatment
CA19-9. Figure 1 summarizes the changes in CA19-9 in response
to neoadjuvant therapy. Overall, a significant decline in the
CA19-9 level was observed after neoadjuvant therapy. The med-
ian post-treatment CA19-9 for all patients was 36 (IQR: 102); 9
(18), 34 (44), 107 (217) and 194 (423) for the normal, low, mod-
erate and high groups, respectively (P < 0.001). A normal post-
treatment CA19-9 was observed in 54 (93%); 40 (51%), 14
(21%) and 5 (19%) of the normal, low, moderate and high
groups, respectively (P < 0.001). Interestingly, four patients with
a normal pre-treatment CA19-9 developed an elevated post-
treatment CA19-9; only one of these patients was resected, and
the remaining three had metastatic disease when restaged after
neoadjuvant therapy. Completion of all intended therapy to
include a pancreatectomy was achieved in 95 (84%) of the 113
patients with a normal post-treatment CA19-9 compared with
73 (62%) of the 118 patients with an elevated post-treatment
CA19-9 (P < 0.001). Of the 50 patients who developed metastatic
disease after neoadjuvant therapy, 40 (80%) had an elevated
post-treatment CA19-9 (P < 0.001).
Peri-operative outcomes
No differences were observed in the operative procedures or
peri-operative outcomes among the CA19-9 subgroups
(Table 2). Among the 168 patients who were resected, a
pancreaticoduodenectomy (PD) was the most common opera-
235 
patients
Normal*:
n = 60
Low:
n = 78
Mod*:
n = 69
High*:
n = 28
54 (90%)
4 (7%)
40 (51%)
93%)38 (49%)
14 (21%)
54 (79%)
5 (19%)
22 (81%)
Normal
Elevated
Post-Tx
CA19-9
43 (79%)
1 (25%)
35 (88%)
93%)27 (71%)
12 (86%)
34 (63%)
5 (100%)
11 (50%)
Normal
ElevatedSuccessfully 
Resected
Pre-Tx
CA19-9
Total 44 (73%) 62 (79%) 46 (67%) 16 (57%)
*Four patients were missing post-treatment CA19-9: 2 in the normal, 1 in the 
moderate, and 1 in the high CA19-9 groups 
Figure 1 Carbohydrate antigen (CA)19-9 response to neoadjuvant therapy
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tion (n = 140, 83%). Venous resections/reconstructions were
performed with 49 (29%) of the 168 pancreatectomies. No dif-
ferences were observed in final (pathological) AJCC stage based
on the pre-treatment CA19-9 group. Node positive disease was
present in 55 (33%) of the 168 patients with a median of 25
(IQR: 13.5) lymph nodes examined per specimen. R0 resec-
tions were obtained in 165 (98%) of the 168 patients. Clavien
grade 3 or higher post-operative complications occurred in 32
(20%) of the 168 patients. The median length of hospital stay
was 9 days (IQR: 4), and 24 (14%) of the 168 patients were
readmitted within 30 days. The 30-day mortality after a pan-
createctomy was 1.2% (n = 2); after successful hospital dis-
charge, one patient experienced an aspiration event that
resulted in a cardiac arrest, anoxic brain injury and subsequent
death, and the other patient had a sudden cardiac arrest after
an uneventful operation on the day of surgery. Of the 168
patients who completed all intended neoadjuvant therapy and
underwent resection of their pancreatic tumour, 86 (51%)
received additional adjuvant therapy.
Survival
The median overall survival of all 235 patients was
23.8 months; 32.2 months, 29.7 months, 21.6 months and
15.9 months for normal, low, moderate and high CA19-9
groups, respectively (log rank P = 0.06) (Fig. 2). This suggests
that there is an inverse relationship between the pre-treatment
CA19-9 value and overall survival in an intention-to-treat
analysis. In an univariable Cox proportional hazards model,
which included all patients, several factors including CCI > 5
(HR 1.86; 95%CI: 1.19–2.9), elevated post-treatment CA19-9
(HR 1.98; 1.38–2.86) and BLR stage (HR 1.89; 1.31–2.72) were
identified as being negatively associated with survival. Comple-
tion of all intended therapy to include successful surgery was
strongly associated with improved survival (HR 0.15: 95%CI:
0.10–0.22) and was the most powerful prognostic factor
by multivariable analysis (HR: 0.20; 95% CI: 0.12–0.29)
(Table 3). Among the 168 patients who completed all intended
therapy including surgery, the median overall survival was
38.4 months; 43.6 months, 44.7 months, 27.2 months and
26.4 months for normal, low, moderate and high CA19-9
groups, respectively (log rank P = 0.72) (Fig. 3). When these
patients were stratified by post-treatment CA19-9 levels, the
median overall survivals for normal versus elevated post-treat-
ment CA19-9 groups were 46.2 and 26.4 months (P = 0.03)
(Fig. 4). Among resected patients, the only prognostic variable
identified in both univariable and multivariable analysis was
the presence of an elevated post-treatment CA19-9, which was
associated with a 1.74-fold increased risk of death (95% CI:
1.08–2.81) (Table 4).
Discussion
A universal tenet of solid tumour oncology is the utilization of
stage-specific therapy to facilitate the selection of the best treat-
ment (based on extent of disease) for each individual patient
in an effort to maximize survival and quality of life for all trea-
ted patients. The success of achieving this goal is predicated on
the ability to discriminate accurately between different disease
stages. Although the staging of PC was once defined by opera-
tive exploration of the abdomen, the current staging of PC is
now based on a precise, objective, radiological classification of
critical tumour-vessel relationships and the presence/absence of
extrapancreatic disease.15 The mainstay of current staging
involves contrast enhanced CT, which provides highly accurate
assessments of such tumour–vessel relationships.20 However,
CT is imperfect at identifying extra-pancreatic metastases, with
10–20% of PC patients discovered to have unanticipated
metastases at the time of laparoscopy or laparotomy.21
Furthermore, in a study of 285 PC patients who underwent a
surgery-first approach, 76% had metastatic disease at the time
Table 2 Operations and peri-operative outcomes
Characteristic Total
N = 168
Normal
n = 44
Low
n = 62
Moderate
N = 46
High
N = 16
P-value
Operation, n (%) 0.30
Pancreaticoduodenectomy 140 (83) 36 (82) 53 (85) 37 (80) 14 (88)
Distal pancreatectomy 21 (13) 7 (16) 7 (11) 7 (15) –
Total pancreatectomy 7 (4) 1 (2) 2 (3) 2 (4) 2 (12)
Venous resection, n (%) 49 (29) 13 (30) 14 (23) 15 (33) 7 (44) 0.36
Arterial resection, n (%) 8 (5) 4 (9) 1 (1) 2 (2) 1 (6) 0.35
Clavien Grade 3+ complication, n (%) 32 (20) 9 (21) 12 (20) 7 (16) 4 (27) 0.84
LOS (days), median (IQR) 9 (4) 9.5 (5) 9 (5) 8 (3) 10.5 (6) 0.29
30 day readmission, n (%) 24 (14) 4 (16) 12 (20) 5 (11) 3 (19) 0.38
30 day mortality 2 (1) 1 (2) 1 (2) – – 0.73
Adjuvant therapy, n (%) 86 (51) 22 (50) 32 (52) 25 (54) 7 (44) 0.90
LOS, length of stay; IQR, interquartile range.
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of first recurrence.5 Rapid autopsies performed on patients
with resected PC also demonstrated that 85% of patients die of
metastatic disease.4 Therefore, the majority of patients with
presumed localized PC have clinically occult metastatic disease
at the time of diagnosis. Furthermore, the current method of
radiographical staging, while highly specific for the assessment
of primary tumour anatomy, cannot discriminate between
patients who have microscopic, radiographically occult meta-
static disease (majority) and patients who may truly have local-
ized disease (minority). As a result, many PC patients who
undergo an immediate surgical resection have metastatic dis-
ease at the time of operation and it is not surprising that the
5-year survival rates for such patients range from 15% to
20%.1
The application of locoregional therapies to a population of
patients with a high likelihood of having systemic disease
should be performed with caution. A rational alternative to a
surgery-first approach for patients with PC is the utilization of
neoadjuvant therapy, which allows for the early delivery of
systemic therapy for the treatment of occult micrometastatic
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Figure 2 Overall survival (OS) of 235 patients with localized pancreatic cancer by pre-treatment with the carbohydrate antigen (CA)19-9
subgroup
Table 3 Cox’s proportional hazards regression analysis – all patients (n = 235)
Variable Univariable Multivariable
HR 95% CI P HR 95% CI P
Age (ref: < 65 years) 0.89 0.63–1.26 0.51
Male Gender (ref: female) 1.36 0.96–1.92 0.08 1.13 0.78–1.62 0.52
CCI >5 (ref: < 5) 1.86 1.19–2.91 0.006 1.30 0.79–2.13 0.29
CA19-9 category
Normal: ≤35 ref ref ref ref ref ref
Low: 36–200 0.90 0.56–1.45 0.66 0.86 0.51–1.44 0.57
Moderate: 201–1000 1.33 0.83–2.14 0.24 0.89 0.49–1.60 0.71
High: >1000 1.76 0.98–3.16 0.06 1.18 0.58–2.36 0.64
Elevated Preop CA19-9 > 35 (ref: < 35) 1.98 1.38–2.86 <0.001 1.48 0.93–2.36 0.10
Borderline Resectable (ref: resectable) 1.89 1.31–2.72 0.001 1.31 0.83–2.06 0.23
Completed Neoadjuvant Tx and Surgery (ref: no) 0.15 0.10–0.22 <0.001 0.20 0.12–0.29 <0.001
Rec’d Adjuvant therapy (ref: no) 0.42 0.28–0.64 <0.001 0.90 0.52–1.53 0.69
HR, hazard ratio; CI, confidence interval; CCI, Charlson’s comorbidity index; CA, carbohydrate antigen.
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disease. Information regarding the disease status (extent of dis-
ease) and its tumour biology (treatment resistant versus sensi-
tive) can be determined during the neoadjuvant treatment
period and at the time of post-treatment restaging. The limita-
tions of pre-treatment radiographical staging in the accurate
identification of metastatic disease can be overcome, in part,
with the assessment of a response to neoadjuvant therapy, as
occult metastatic disease is unmasked at the time of post-treat-
ment restaging in 26–34% of patients.22,23 Currently, all consen-
sus guidelines recommend neoadjuvant therapy for patients
with BLR PC.24,25 However, as the majority of patients with PC
have metastatic disease at diagnosis (regardless of stage of dis-
ease), several institutions (including the authors) utilize neoad-
juvant therapy for the management of all patients with localized
PC, including those with resectable disease. In contrast to a sur-
gery-first approach, the median overall survival of patients with
localized PC who completed all intended neoadjuvant therapy
to include successful surgery ranges from 31 to 34 months.22,23
Despite the nearly 12-month prolongation in overall survival
among patients who are able to complete all intended neoadju-
vant therapy and surgery (compared with those treated with
surgery first), it is important to note that disease recurrence
remains common. Additional prognostic markers are needed to
discriminate further which patients are likely to develop early
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Figure 4 Overall survival of 168 patients with resected pancreatic cancer after neoadjuvant therapy by post-treatment with carbohydrate
antigen (CA)19-9 status
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Figure 3 Overall survival (OS) of 168 patients with resected pancreatic cancer after neoadjuvant therapy by pre-treatment with the
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disease recurrence after completion of all intended therapy and
those likely to have a prolonged survival benefit.
CA19-9 is a sialyated Lewis antigen that has been exten-
sively studied in patients with PC. Several reports have dem-
onstrated that pre-operative CA19-9 is associated with
tumour stage, resectability, the risk of recurrence and survival
in patients with localized PC treated with a surgery-first
approach.7,9,12,26,27 One of the first studies to describe the
prognostic importance of CA19-9 examined 176 patients with
localized PC.7 CA19-9 was found to correlate with the AJCC
pathological stage, as well as post-resection survival. Of note,
patients with pre-operative CA19-9 values greater than
1000 U/ml had a median overall survival of only 12 months
as compared to 28 months for patients with CA19-9 values
< 1000 U/ml. Similarly, in the largest study examining pre-
treatment CA19-9, which involved 1626 patients with local-
ized PC, Hartwig et al. observed a strong inverse relationship
between pre-operative CA19-9 levels and both R0 resection
rates and overall survival.12 In their study, 312 patients had a
pre-treatment CA19-9 level >1000 U/ml and in this sub-
group, there were no 5-year survivors; the median overall
survival after resection was approximately 12 months. As a
result, the authors concluded that patients with CA19-9 levels
>1000 are at a high risk for the development of metastatic
disease and a neoadjuvant treatment approach should be
considered.
In the present study, we also observed that pre-treatment
CA19-9 was inversely associated with survival (Fig. 2). We
observed that higher pre-treatment CA19-9 was associated with
failure to complete all intended therapy, specifically due to the
development of metastatic disease that precluded surgical
resection. Interestingly, among patients who were able to com-
plete all intended neoadjuvant therapy and successful surgery,
the prognostic value of the pre-treatment CA19-9 was attenu-
ated (Fig. 3). Although there were clinically significant differ-
ences in overall survival between the pre-treatment CA19-9
subgroups, this did not reach statistical significance. Further-
more, in a multivariate Cox’s proportional hazards model, the
pre-treatment CA19-9 subgroup was not a prognostic marker
for survival duration. Of the 175 patients with elevated pre-
treatment CA19-9, 173 had evaluable post-treatment CA19-9
that became normal in 59 (34%) patients, suggesting a robust
therapeutic response to neoadjuvant therapy. Of the 28
patients with pre-treatment CA19-9 greater than 1000 U/ml,
16 (57%) completed all intended neoadjuvant therapy and sur-
gery, and these 16 patients had a median overall survival of
26.4 months. Although high pre-treatment CA19-9 levels have
been associated with a poor overall survival, in our experience,
over 50% of such patients were able to complete all intended
neoadjuvant therapy including surgery and they had a median
overall survival of >2 years. Therefore, elevated pre-treatment
CA19-9 should not be a contraindication to embarking on a
potentially curative programme of neoadjuvant treatment
sequencing.
Changes in CA19-9 levels may be associated with a tumour
response, and the normalization of CA19-9 after a surgical
resection has been associated with an improved prognosis in
several surgical series.7,12,26 Among patients with advanced PC,
the early decrease in CA19-9 levels was associated with
objective changes in radiographical response and sur-
vival.11,28,29 Similarly, among patients with localized PC, a
decrease in CA19-9 in response to neoadjuvant therapy has
previously been reported to correlate with overall survival.13,14
In a study of 78 patients with localized PC, a 50% reduction
in pre-treatment CA19-9 after neoadjuvant therapy was associ-
ated with an improved overall survival (28 versus 11 months,
Table 4 Cox’s proportional hazards regression analysis-resected patients (n = 168)
Variable Univariable Multivariable
HR 95% CI P HR 95% CI P
Age (ref: < 65 years) 0.90 0.57–1.43 0.51
Male Gender (ref: female) 1.13 0.71–1.79 0.60
CCI >5 (ref: < 5) 1.13 0.51–2.46 0.76
CA19-9 category
Normal: ≤35 ref ref ref
Low: 36–200 0.88 0.49–1.62 0.70
Moderate: 201–1000 1.33 0.61–2.14 0.69
High: >1000 1.34 0.58–3.08 0.50
Elevated Preop CA19-9 > 35 (ref: < 35) 1.67 1.05–2.67 0.03 1.74 1.08–2.81 0.02
Borderline Resectable (ref: resectable) 1.42 0.89–2.26 0.14 1.55 0.97–2.48 0.07
Node positive (ref: node negative) 1.43 0.88–2.34 0.14 1.37 0.84–2.24 0.21
Rec’d Adjuvant therapy (ref: no) 0.82 0.51–1.31 0.40
HR, hazard ratio; CI, confidence interval; CCI, Charlson’s comorbidity index; CA, carbohydrate antigen.
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P < 0.0001).13 In another study of 82 patients with localized
PC, a decline in CA19-9 after neoadjuvant therapy was also
associated with an improved survival (25.7 months versus
10.4 months, P = 0.01).14 In the present study of 235 patients,
we observed that the normalization of CA19-9, after neoadju-
vant therapy, was associated with the successful completion of
all intended therapy in a univariable logistic regression model
(HR: 1.98; P < 0.001), but lost statistical significance in a mul-
tivariable model (HR: 1.47; P = 0.10). Not surprisingly, the
strongest prognostic factor for survival was the completion of
all intended neoadjuvant therapy and surgery. However, of the
168 patients in whom successful resection was achieved, the
single most powerful prognostic factor for survival was the
normalization of post-treatment/pre-operative CA19-9. Patients
with elevated post-treatment/pre-operative CA19-9 had a 1.8-
fold increased risk of death as compared with patients with
normal post-treatment CA19-9 (P = 0.02). As such, our present
study confirms earlier reports that post-treatment/pre-operative
CA19-9 is an important prognostic indicator for overall sur-
vival among patients who undergo a pancreatectomy.
The prognostic value of post-treatment/pre-operative
CA19-9 adds additional support to the hypothesis that the
delivery of systemic therapy prior to surgery may be more
effective than the delivery of systemic therapy in the post-
operative setting. In the study by Hartwig et al., patients
with pre-operative CA19-9 levels > 1000, who underwent a
pancreatectomy, had a survival duration of approximately
12 months. Presumably all patients were offered adjuvant
therapy owing to their high pre-operative CA19-9 levels,
although the proportion of patients who received adjuvant
therapy was not provided. We know that adjuvant therapy
cannot be successfully delivered to all patients after a major
pancreatic operation. This is one of the significant limita-
tions of a surgery-first treatment approach.30 Importantly, in
the present report, 16 (57%) of the 28 patients with a pre-
treatment CA19-9 > 1000, who successfully completed all
intended therapy, had a median survival of 24 months –
double that in the report by Hartwig and colleagues. Among
this high-risk subgroup, as expected, only 44% received
adjuvant therapy. Why is the survival of these two cohorts
of high-risk patients so disparate? Could the survival advan-
tage be because of treatment sequencing? The improvement
in overall survival in the neoadjuvant treatment group
(24 months versus 12 months for surgery-first) may be
owing to the delivery of early systemic therapy in an
immune-competent patient. Although several millennia of
experience support the use of surgical resection to impart a
cure in patients with localized PC, the vast majority of
patients who are treated with a surgery-first strategy harbour
distant metastases, even if radiographically occult. It is now
accepted that major surgery suppresses the immune system
for several days and that more invasive procedures are asso-
ciated with longer and more profound immunosuppression.31
Suppression of cell-mediated immunity occurs through mul-
tiple mechanisms including the release of tumour cells, the
reduction of antiangiogenic factors, and the induction of
growth factors, which all can be further modified by tissue
damage, the use of blood products, hypothermia and pain
management.32 Immunosuppression has long been recognized
to be associated with an increase in metastatic disease pro-
gression as observed in transplant patients and those with
AIDS.33,34 Whether or not the immunosuppression associated
with a pancreatic resection is significant enough to enhance
disease progression at distant sites is unknown, but this may
have important implications with regards to treatment
sequencing. For the majority of patients who have subclinical
metastatic disease at the time of diagnosis, the effect of sur-
gically induced immunosuppression (surgery first approach)
may be very important – especially for those whose disease
would have been sensitive to the selected systemic therapy.
There are some well-described limitations of the use of
CA19-9 as a prognostic biomarker. First, approximately 10%
of Caucasians and 22% of African Americans lack either the
Lewis gene or the secretory gene, and, therefore, will not have
an elevated CA19-9 even in the presence of PC.35,36 In addi-
tion, CA19-9 can be elevated in benign pancreatic disease and
the setting of cholestasis.37,38 Nevertheless, a wealth of data
exists to support the prognostic value of CA19-9 levels in
patients with PC and the routine incorporation of CA19-9 at
the time of restaging assessments may provide important
insight into treatment response. Given the limitations of radio-
graphic staging that underestimates disease extent in most
patients with PC, more sensitive techniques are needed which
prospectively incorporate validated biomarkers. Blood-based
biomarkers, whether biochemical, such as CA19-9, or cellular,
such as circulating tumour cells, may be critical to the design
of future clinical trials which stratify patients by prognostic
biomarkers rather than relying solely on radiographical or
pathological staging (Fig. 5).
Conclusions
Pre-treatment serum CA19-9 levels are clinically useful in
assessing the risk for decreased survival in patients with PC
who are treated with neoadjuvant therapy. However, even
patients with very high pre-treatment CA19-9 levels may derive
a meaningful survival benefit with a neoadjuvant approach.
Such patients can be identified by their decline in post-treat-
ment CA19-9 level in response to neoadjuvant therapy. Impor-
tantly, the CA19-9 response to induction therapy provides a
window through which we can begin to understand a complex
tumour biology which defines PC – additional biomarkers
under development will add to the value of post-treatment/
pre-operative CA19-9 and provide physicians a much more
accurate prediction of whether surgery will provide a clinically
meaningful benefit to an individual patient.
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